Helix BioPharma Corp. has seen a notable uptick in its stock price, gaining over 2% in the last trading session.
On the TSX, Helix BioPharma Corp. (HBP.TO) closed up by 2.14%, reaching CA$1.43. This rise comes amid strategic financial maneuvers and growing investor interest in the biotech sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$114.57M
52W high
$5.40
52W low
$0.98
1W change
+2.07%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 68.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+68.9% Upside
Current Price
C$1.48
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
-43.1%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.66 |
| 60 trading days | C$1.34 | C$1.05 – C$1.69 |
| 90 trading days | C$1.27 | C$0.95 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may want to keep an eye on Helix BioPharma's ongoing developments as the company positions itself for potential growth and expansion in the competitive biotech landscape.
Market Cap Reaches CA$106.9 Million
With a market cap of CA$106.9 million, Helix BioPharma is still in the early stages of its growth trajectory, making it a speculative investment.
Bull case
The recent positive movement in Helix BioPharma's stock may be driven by strategic initiatives like their recent private placement. This move aims to attract more institutional investment and prepare for a NASDAQ uplisting, which could boost investor confidence.
Bear case
Despite the recent gains, Helix BioPharma's financial health remains uncertain. The company has struggled with consistent profitability and does not offer a dividend yield, which might be a concern for more cautious investors.
Recent Stock Performance
Advertisement
Helix BioPharma Corp. saw its stock price increase by 2.14% in the last trading session, closing at CA$1.43. This upward trend is a positive signal for investors, especially in the volatile biotech sector.
Strategic Initiatives Fueling Growth
The company recently closed a non-brokered private placement, raising funds to support its institutional investment goals and potential NASDAQ uplisting. These moves could enhance investor confidence and drive further interest in HBP.TO.
Considerations for Investors
While the recent gains are encouraging, investors should weigh the company's financial stability and lack of profitability against the potential for future growth. Keeping an eye on Helix BioPharma's developments will be crucial for making informed investment decisions.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
